dog on the beach

Boehringer Ingelheim and Invetx Announce Strategic Collaboration to Advance Monoclonal Antibody Biotherapeutics in Animal Health

September 27, 2021

Collaboration Focused on Discovery, Development and Commercialization of  Novel Veterinary Medicines Ingelheim, Germany and Boston, MA- September 27, 2021- Boehringer Ingelheim, a global leader in

Invetx Announces Initiation of First Clinical Study in Dogs with IVX-01, its Novel Monoclonal Antibody Featuring Half-Life Extension

September 20, 2021

Company Appoints Dr. Robert Zolynas as Vice President, Clinical Development & Regulatory Affairs Boston, MA- September 20, 2021- Invetx, a pioneer in protein-based therapeutics for

Former Head of Boehringer Ingelheim Animal Health, Dr. Joachim Hasenmaier, Joins Invetx Board of Directors

January 6, 2021

BOSTON, Mass. – January 6, 2021 – Invetx, a pioneer in protein-based therapeutics for animal health, announced today that Dr. Joachim Hasenmaier has joined the

AbCellera and Invetx Expand Multi-Year Antibody Discovery Collaboration in Animal Health

November 19, 2020

VANCOUVER, British Columbia, and BOSTON, November 19, 2020 – AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that

Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team

September 30, 2020

New Investors Include Casdin Capital and Tekla Capital   Antibody Development Experts Bill Brondyk, PhD, Named Chief Scientific Officer and Colin Giles, PhD, Chief Development

Invetx Announces Industry-Leading Antibody Discovery Platform to Develop Portfolio of Novel Therapeutics for Animal Health

July 16, 2020

Platform Leverages Best-in-Class Technologies from AbCellera, Twist Bioscience and WuXi Biologics BOSTON, Mass. – July 16, 2020 – Invetx, a pioneer in protein-based therapeutics for

Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats

July 16, 2020

SOUTH SAN FRANCISCO and BOSTON, Mass. – July 16, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering

Invetx Announces $15 Million Series A Financing and Industry-leading Partnerships for Animal Biopharmaceutical Development

February 24, 2020

Anterra Capital leads financing to advance Invetx’s pipeline of veterinary biologic drugs leveraging breakthroughs in human biopharma Global biologics CDMO WuXi Biologics makes equity investment

Invetx